Nichole Burns, | |
21 Montauk Avene, New London, CT 06320-4906 | |
(860) 271-4715 | |
(860) 271-4797 |
Full Name | Nichole Burns |
---|---|
Gender | Female |
Speciality | Social Worker - Clinical |
Location | 21 Montauk Avene, New London, Connecticut |
Accepts Medicare Assignments | Medicare enrolled and may accept medicare through third-party reassignment. May prescribe medicare part D drugs. |
Identifier | Type | State | Issuer |
---|---|---|---|
1003230624 | NPI | - | NPPES |
008059339 | Medicaid | CT |
Taxonomy | Type | License (State) | Status |
---|---|---|---|
101YM0800X | Counselor - Mental Health | (* (Not Available)) | Secondary |
1041C0700X | Social Worker - Clinical | (* (Not Available)) | Primary |
Entity Name | Sound Community Services Inc |
---|---|
Entity Type | Part B Supplier - Clinic/group Practice |
Entity Identifiers | NPI Number: 1396700886 PECOS PAC ID: 7517981517 Enrollment ID: O20060117001127 |
News Archive
The first peer-reviewed study in North America examining the timing between the first and second doses of COVID-19 mRNA vaccines shows that a longer dose interval leads to a stronger immune response. The study is funded by the Government of Canada through its COVID-19 Immunity Task Force.
Aetna today announced that members who enroll in its 2010 Medicare plans will have access to enhanced services called medication therapy management (MTM) aimed at helping them safely and effectively take medications prescribed by their physician. MTM, which will be delivered by Mirixa Corporation, brings together pharmacists, patients, physicians and other health care professionals to help patients with their medications.
mtm laboratories, a privately held diagnostics company developing, manufacturing and globally commercializing in vitro diagnostics for cervical cancer early detection and diagnosis, today announced the signing for an additional tranche of Euro 7 million to its Series C funding. This addition is a formal expansion of the Company's last Series C in March 2008 and increases the total for the round to Euro 39 million (USD 57 million) in equity.
New research led by scientists at The Scripps Research Institute (TSRI), International AIDS Vaccine Initiative (IAVI) and The Rockefeller University shows in mice that an experimental vaccine candidate designed at TSRI can stimulate the immune system activity necessary to stop HIV infection. The findings could provide key information for the development of an effective AIDS vaccine.
› Verified 4 days ago
Mailing Address | Practice Location Address |
---|---|
Nichole Burns, 21 Montauk Avene, P.o. Box 390, New London, CT 06320-6344 Ph: (860) 271-4715 | Nichole Burns, 21 Montauk Avene, New London, CT 06320-4906 Ph: (860) 271-4715 |
News Archive
The first peer-reviewed study in North America examining the timing between the first and second doses of COVID-19 mRNA vaccines shows that a longer dose interval leads to a stronger immune response. The study is funded by the Government of Canada through its COVID-19 Immunity Task Force.
Aetna today announced that members who enroll in its 2010 Medicare plans will have access to enhanced services called medication therapy management (MTM) aimed at helping them safely and effectively take medications prescribed by their physician. MTM, which will be delivered by Mirixa Corporation, brings together pharmacists, patients, physicians and other health care professionals to help patients with their medications.
mtm laboratories, a privately held diagnostics company developing, manufacturing and globally commercializing in vitro diagnostics for cervical cancer early detection and diagnosis, today announced the signing for an additional tranche of Euro 7 million to its Series C funding. This addition is a formal expansion of the Company's last Series C in March 2008 and increases the total for the round to Euro 39 million (USD 57 million) in equity.
New research led by scientists at The Scripps Research Institute (TSRI), International AIDS Vaccine Initiative (IAVI) and The Rockefeller University shows in mice that an experimental vaccine candidate designed at TSRI can stimulate the immune system activity necessary to stop HIV infection. The findings could provide key information for the development of an effective AIDS vaccine.
› Verified 4 days ago